The GISCO study plans to determine whether 8-week therapy is just as effective as 26-week cortisone therapy for treating giant cell arteritis
* with tocilizumab, * while using less cortisone.
Patients diagnosed with giant cell arteritis
Start of tocilizumab treatment at baseline as part of routine clinical practice
Receive ≥ 20 mg/day prednisone (or equivalent) at baseline
Written informed consent
Treated with any investigational drug of chemical or biologic nature within a minimum of 30 days or 5 half-lives (whichever is longer) prior to the first dose of tocilizumab.
Single group
Prednisone
DrugParticipant randomization to receive shortened (8 weeks) glucocorticoid taper upon initiation of a glucocorticoid-sparing agent.
Prednisone
DrugParticipant randomization to receive standard (26 weeks) glucocorticoid taper upon initiation of a glucocorticoid-sparing agent.
Absence of a major relapse from randomization to 52 weeks
Composite endpoint. Pairwise comparisons of each patient from the control arm with each patient of the experimental arm.
Cumulative glucocorticoid exposure from randomization to 52 weeks
Composite endpoint. Pairwise comparisons of each patient from the control arm with each patient of the experimental arm.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
